Literature DB >> 2681438

Prophylaxis of Pneumocystis carinii pneumonia: an update.

J A Kovacs1, H Masur.   

Abstract

Note from Dr. Merle A. Sande--We have recently come to appreciate the fact that successful chemotherapy of opportunistic infections in patients with AIDS is akin to treatment of certain malignancies: In both instances, induction, followed by maintenance, therapy is required. Although control of initial infections is usually successful with current regimens, relapse is common if lifelong prophylactic or suppressive therapy is not used. This is true in human immunodeficiency virus (HIV)-infected individuals with Pneumocystis carinii pneumonia, cryptococcosis, histoplasmosis, toxoplasmosis, and cytomegaloviral infection. Because Drs. Joseph A. Kovacs and Henry Masur of the National Institutes of Health have been instrumental in developing strategies for the management of P. carinii pneumonia, they were asked to discuss their current approach to chemoprophylaxis of this infection in this AIDS Commentary.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2681438     DOI: 10.1093/infdis/160.5.882

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  14 in total

Review 1.  Opportunistic protozoan infections in human immunodeficiency virus disease: review highlighting diagnostic and therapeutic aspects.

Authors:  A Curry; A J Turner; S Lucas
Journal:  J Clin Pathol       Date:  1991-03       Impact factor: 3.411

Review 2.  Clinical management of the complications of HIV infection.

Authors:  T G Cooney
Journal:  J Gen Intern Med       Date:  1991 Jan-Feb       Impact factor: 5.128

Review 3.  Pneumocystis carinii, an opportunist in immunocompromised patients.

Authors:  M S Bartlett; J W Smith
Journal:  Clin Microbiol Rev       Date:  1991-04       Impact factor: 26.132

Review 4.  Pneumocystis carinii pneumonia after 40 years.

Authors:  M Nouza
Journal:  Infection       Date:  1992 May-Jun       Impact factor: 3.553

5.  Inhaled Pentamidine Therapy for Pneumocystis carinii Pneumonia.

Authors:  M J Clement
Journal:  West J Med       Date:  1990-07

6.  Improved rat model of Pneumocystis carinii pneumonia: induced laboratory infections in Pneumocystis-free animals.

Authors:  C J Boylan; W L Current
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

7.  High risk of developing toxoplasmic encephalitis in AIDS patients seropositive to Toxoplasma gondii.

Authors:  R Zangerle; F Allerberger; P Pohl; P Fritsch; M P Dierich
Journal:  Med Microbiol Immunol       Date:  1991       Impact factor: 3.402

8.  Pharmacokinetics and adverse effects of 20-mg/kg/day trimethoprim and 100-mg/kg/day sulfamethoxazole in healthy adult subjects.

Authors:  R C Stevens; S C Laizure; C L Williams; D S Stein
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

9.  Efficacy of pyrimethamine/sulfadoxine in the prevention of toxoplasmic encephalitis relapses and Pneumocystis carinii pneumonia in HIV-infected patients.

Authors:  B Ruf; D Schürmann; F Bergmann; W Schüler-Maué; T Grünewald; H J Gottschalk; H Witt; H D Pohle
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-05       Impact factor: 3.267

10.  Microculture screening assay for primary in vitro evaluation of drugs against Pneumocystis carinii.

Authors:  J C Comley; R J Mullin; L A Wolfe; M H Hanlon; R Ferone
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.